---
title: "Rexulti (brexpiprazole), all indications: Safety questions"
description: "Safety questions on Rexulti (brexpiprazole) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings. Questions: Is Rexulti a controlled substance? Does Rexulti prolong the QT interval? What is the Rexulti boxed warning for suicidal thoughts and dementia-related psychosis? Can Rexulti raise blood sugar or cause diabetes? 13 further questions follow. 17 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/rexulti/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole), all indications: Safety questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)  
Indication pages: [Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)

## Safety

<a id="rexulti-controlled-substance"></a>

### Is Rexulti a controlled substance?

> “REXULTI contains brexpiprazole, which is not a controlled substance.”

Source: [REXULTI: Prescribing information, page 24, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=24)

> “Animals given access to REXULTI did not self-administer the drug, suggesting that REXULTI does not have 
> rewarding properties.”

Source: [REXULTI: Prescribing information, page 24, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=24)

<a id="rexulti-qt-prolongation"></a>

### Does Rexulti prolong the QT interval?

> “At a dose 3 times the MRHD for the treatment of schizophrenia and 4 times the MRHD for adjunctive therapy 
> to antidepressants for the treatment of MDD or agitation associated with dementia due to Alzheimer’s disease, 
> REXULTI does not prolong the QTc interval to any clinically relevant extent.”

Source: [REXULTI: Prescribing information, page 25, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=25)

<a id="rexulti-withdrawal"></a>

### Does stopping Rexulti cause withdrawal symptoms?

> “Humans and animals that received chronic REXULTI administration did not demonstrate any withdrawal signs 
> upon drug discontinuation. This suggests that REXULTI does not produce physical dependence.”

Source: [REXULTI: Prescribing information, page 24, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=24)

<a id="rexulti-overdose"></a>

### What should be done after a Rexulti overdose?

> “There is limited clinical trial experience regarding human overdosage with REXULTI.  
> Management of a REXULTI overdose should concentrate on supportive therapy, maintaining an adequate 
> airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring 
> should continue until the patient recovers.”

Source: [REXULTI: Prescribing information, page 24, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=24)

> “Consider contacting the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage 
> management recommendations. 
> Oral activated charcoal and sorbitol (50 g/240 mL), administered one hour after ingesting oral REXULTI, 
> decreased brexpiprazole Cmax and area under the curve (AUC) by approximately 5% to 23% and 31% to 39% 
> respectively; however, there is insufficient information available on the therapeutic potential of activated 
> charcoal in treating an overdose with REXULTI. 
> There is no information on the effect of hemodialysis in treating an overdose with REXULTI; hemodialysis is 
> unlikely to be useful because brexpiprazole is highly bound to plasma proteins.”

Source: [REXULTI: Prescribing information, page 25, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=25)

## Warnings

<a id="rexulti-boxed-warning"></a>

### What is the Rexulti boxed warning for suicidal thoughts and dementia-related psychosis?

> “WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED 
> PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS 
> Increased Mortality in Elderly Patients with Dementia-Related Psychosis  
> Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an 
> increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related 
> psychosis without agitation associated with dementia due to Alzheimer’s disease [see Warnings 
> and Precautions (5.1)].  
> Suicidal Thoughts and Behaviors 
> Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients and 
> young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for 
> clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and 
> Precautions (5.2)]. The safety and effectiveness of REXULTI have not been established in pediatric 
> patients with MDD [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].”

Source: [REXULTI: Prescribing information, page 3, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=3)

<a id="rexulti-blood-sugar"></a>

### Can Rexulti raise blood sugar or cause diabetes?

> “Hyperglycemia and diabetes mellitus, in some cases extreme and associated with diabetic ketoacidosis 
> hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics. There have 
> been reports of hyperglycemia in patients treated with REXULTI. Assess fasting plasma glucose before or 
> soon after initiation of antipsychotic medication and monitor periodically during long-term treatment.”

Source: [REXULTI: Prescribing information, page 7, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=7)

> “In the 6-week placebo-controlled, fixed-dose clinical studies in adult patients with MDD, the proportions of 
> patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) and borderline (≥100 and 
> <126 mg/dL) to high were similar in patients treated with REXULTI and placebo.”

Source: [REXULTI: Prescribing information, page 8, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=8)

<a id="rexulti-cholesterol-triglycerides"></a>

### Does Rexulti raise cholesterol or triglycerides?

> “Atypical antipsychotics cause adverse alterations in lipids. Before or soon after initiation of antipsychotic 
> medication, obtain a fasting lipid profile at baseline and monitor periodically during treatment.”

Source: [REXULTI: Prescribing information, page 8, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=8)

> “In the 6-week placebo-controlled, fixed-dose clinical studies in adult patients with MDD, changes in fasting total 
> cholesterol, LDL cholesterol, and HDL cholesterol were similar in REXULTI- and placebo-treated patients. 
> Table 3 shows the proportions of patients with changes in fasting triglycerides. 
> Table 3 
> Change in Fasting Triglycerides in the 6-Week Placebo-Controlled, Fixed-Dose MDD 
> Studies 
> Proportion of Patients with Shifts Baseline to Post-Baseline 
> Triglycerides 
> Placebo 
> 1 mg/day 
> 2 mg/day 
> 3 mg/day 
> Normal to High 
> (<150 mg/dL to ≥200 and <500 mg/dL) 
> 6% 
> (15/257)* 
> 5% 
> (7/145)* 
> 13% 
> (15/115)* 
> 9% 
> (13/150)* 
> Normal/Borderline to Very High 
> (<200 mg/dL to ≥500 mg/dL) 
> 0% 
> (0/309)* 
> 0% 
> (0/177)* 
> 0.7% 
> (1/143)* 
> 0% 
> (0/179)* 
> *denotes n/N where N=the total number of patients who had a measurement at baseline and at least one post-baseline result; n=the 
> number of patients with shift”

Source: [REXULTI: Prescribing information, page 9, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=9)

Note: Table 3 columns are placebo, REXULTI 1 mg/day, 2 mg/day, and 3 mg/day, in that order.

<a id="rexulti-tardive-dyskinesia"></a>

### Can Rexulti cause tardive dyskinesia?

> “Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may 
> develop in patients treated with antipsychotic drugs. The risk appears to be highest among the elderly, 
> especially elderly women, but it is impossible to predict which patients will develop the syndrome. Whether 
> antipsychotic drugs differ in their potential to cause tardive dyskinesia is unknown. 
> The risk of tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the 
> duration of treatment and the cumulative dose increases. The syndrome can develop after relatively brief 
> treatment periods, at low doses. It may also occur after discontinuation of treatment.”

Source: [REXULTI: Prescribing information, page 7, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=7)

> “If signs and symptoms of tardive dyskinesia appear in a patient treated with REXULTI, drug discontinuation 
> should be considered. However, some patients may require treatment with REXULTI despite the presence of 
> the syndrome.”

Source: [REXULTI: Prescribing information, page 7, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=7)

<a id="rexulti-nms"></a>

### Can Rexulti cause neuroleptic malignant syndrome (NMS)?

> “Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association 
> with administration of antipsychotic drugs, including REXULTI.”

Source: [REXULTI: Prescribing information, page 6, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=6)

> “Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of 
> autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). 
> Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute 
> renal failure.  
> If NMS is suspected, immediately discontinue REXULTI and provide intensive symptomatic treatment and 
> monitoring.”

Source: [REXULTI: Prescribing information, page 7, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=7)

<a id="rexulti-compulsive-behaviors"></a>

### Can Rexulti cause compulsive gambling or other urges?

> “Post-marketing case reports suggest that patients can experience intense urges, particularly for gambling, and 
> the inability to control these urges while taking REXULTI. Other compulsive urges, reported less frequently, 
> include sexual urges, shopping, eating, or binge eating, and other impulsive or compulsive behaviors. Because 
> patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their 
> caregivers specifically about the development of new or intense gambling urges, compulsive sexual urges, 
> compulsive shopping, binge or compulsive eating, or other urges while being treated with REXULTI. In some 
> cases, although not all, urges were reported to have stopped when the dose was reduced, or the medication 
> was discontinued. Compulsive behaviors may result in harm to the patient and others if not recognized. 
> Consider dose reduction or stopping the medication if a patient develops such urges.”

Source: [REXULTI: Prescribing information, page 12, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=12)

<a id="rexulti-neutropenia"></a>

### Can Rexulti lower white blood cell counts?

> “Leukopenia and neutropenia have been reported during treatment with antipsychotic agents. Agranulocytosis 
> (including fatal cases) has been reported with other agents in this class. 
> Possible risk factors for leukopenia and neutropenia include pre-existing low white blood cell count (WBC) or 
> absolute neutrophil count (ANC) and history of drug-induced leukopenia or neutropenia. In patients with a pre-
> existing low WBC or ANC or a history of drug-induced leukopenia or neutropenia, perform a complete blood 
> count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of 
> REXULTI at the first sign of a clinically significant decline in WBC in the absence of other causative factors.  
> Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat 
> promptly if such symptoms or signs occur. Discontinue REXULTI in patients with absolute neutrophil count 
> <1000/mm<sup>3</sup> and follow their WBC until recovery.”

Source: [REXULTI: Prescribing information, page 12, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=12)

<a id="rexulti-falls"></a>

### Does Rexulti increase the risk of falls?

> “Antipsychotics, including REXULTI, may cause somnolence, postural hypotension, motor, and sensory 
> instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, 
> conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating 
> antipsychotic treatment and recurrently for patients on long-term antipsychotic treatment.”

Source: [REXULTI: Prescribing information, page 13, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=13)

<a id="rexulti-stroke-dementia"></a>

### Does Rexulti increase stroke risk in older adults with dementia?

> “In placebo-controlled trials in elderly patients with dementia, patients randomized to risperidone, aripiprazole, 
> and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. REXULTI 
> is not approved for the treatment of patients with dementia-related psychosis without agitation associated with 
> dementia due to Alzheimer’s disease [see Boxed Warning, Warnings and Precautions (5.1)].”

Source: [REXULTI: Prescribing information, page 6, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=6)

<a id="rexulti-seizures"></a>

### Can Rexulti cause seizures?

> “Like other antipsychotic drugs, REXULTI may cause seizures. This risk is greatest in patients with a history of 
> seizures or with conditions that lower the seizure threshold. Conditions that lower the seizure threshold may be 
> more prevalent in older patients.”

Source: [REXULTI: Prescribing information, page 13, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=13)

<a id="rexulti-overheating"></a>

### Can Rexulti affect body temperature regulation?

> “Atypical antipsychotics may disrupt the body’s ability to reduce core body temperature. Strenuous exercise, 
> exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core 
> body temperature; use REXULTI with caution in patients who may experience these conditions.”

Source: [REXULTI: Prescribing information, page 13, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=13)

> “Counsel patients regarding appropriate care in avoiding overheating and dehydration [see Warnings and 
> Precautions (5.12)].”

Source: [REXULTI: Prescribing information, page 39, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=39)

<a id="rexulti-swallowing"></a>

### Can Rexulti cause trouble swallowing?

> “Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Antipsychotic drugs, 
> including REXULTI, should be used cautiously in patients at risk for aspiration.”

Source: [REXULTI: Prescribing information, page 13, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=13)

<a id="rexulti-contraindications"></a>

### Who should not take Rexulti (contraindications)?

> “REXULTI is contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its 
> components. Reactions have included rash, facial swelling, urticaria, and anaphylaxis.”

Source: [REXULTI: Prescribing information, page 5, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=5)

## Related pages
- [Medical information: Rexulti (brexpiprazole): All indications](https://www.evicenter.com/medical-information/rexulti)
- [Indication](https://www.evicenter.com/medical-information/rexulti/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/rexulti/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/rexulti/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rexulti/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rexulti/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/rexulti/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti/access-and-coverage)
